Clinical Scenario 2, Discussion of Treatment Goals, AUGMENT-101, and Antifungal Selection in Relapsed KMT2A-Rearranged AML

The moderator presents Clinical Scenario 2, a 34-year-old woman with relapsed KMT2A-rearranged AML who has controlled paroxysmal atrial fibrillation, takes posaconazole, and has small children at home. The panelists discuss her goals and options: revumenib is the only approved agent for KMT2A-rearranged disease, single-agent therapy vs combinations, and the goal would be to get her to transplant as transplant is the likely path to cure and then maintenance post-transplant. They clarify that a KMT2A partial tandem duplication is different from a KMT2A rearrangement and was excluded from AUGMENT-101. The segment ends on discussion of antifungal preferences in this patient clinical scenario.